• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    26.45 +0.18 (+0.70%)
    Streaming Delayed Price Updated: 11:24 AM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 409,334
    Open 26.30
    Bid (Size) 26.44 (3)
    Ask (Size) 26.45 (4)
    Prev. Close 26.26
    Today's Range 26.15 - 26.48
    52wk Range 25.92 - 31.93
    Shares Outstanding 388,132,400
    Dividend Yield 3.03%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -6.46%
    -6.46%
    1 Month
    -3.77%
    -3.77%
    3 Month
    -13.04%
    -13.04%
    6 Month
    -2.31%
    -2.31%
    1 Year
    -15.81%
    -15.81%

    More News

    Read More
    Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
    From Royalty Pharma plc
    Via GlobeNewswire
    NASDAQ:RPRX: good value for what you're paying.
    Via Chartmill
    Looking Into Royalty Pharma's Recent Short Interest
    Via Benzinga
    NASDAQ:RPRX is an undervalued gem with solid fundamentals.
    Via Chartmill
    Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
    Via Benzinga
    Exposures Product Safety
    Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
    Via Investor's Business Daily
    Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
    From Royalty Pharma plc
    Via GlobeNewswire
    Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
    Via Benzinga
    Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    From Royalty Pharma plc; Cytokinetics
    Via GlobeNewswire
    7 Dividend Stocks to Buy at a 52-Week Low
    Via InvestorPlace
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Royalty Pharma Reports First Quarter 2024 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
    From Royalty Pharma plc
    Via GlobeNewswire
    Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
    Via Benzinga
    Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Declares Second Quarter 2024 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    3 Pharma Stocks to Sell in April Before They Crash & Burn
    Via InvestorPlace
    Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
    Via InvestorPlace
    April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
    Via InvestorPlace
    The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
    Via InvestorPlace
    For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.